SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB₁ and CB₂ cannabinoid receptors. SDB-005 is the
indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.